Sage Journals: Discover world-class research

Abstract

The explosion of genuine high throughput technologies has allowed large compound libraries to be screened with ever-increasing biological specificity, exacerbating the problem of lead candidate selection for subsequent drug development. To avoid creating a bottleneck, compounds identified from the high throughput screens undergo lead optimisation by employing medium-throughput screens which permit ranking in terms of their basic absorption, distribution, metabolism, excretion (ADME) and toxicological properties. The historical role of the preclinical scientist in the drug discovery/development continuum has been to perform ADME and toxicology studies, simply to support the regulatory submission of lead candidates. This situation is, however, changing with the development of preclinical lead optimisation technologies facilitating the selection of leading candidates, thereby bridging the gap between high throughput efficacy screens and conventional safety assessment programmes.

Keywords

in vitro lead optimisation preclinical lead optimisation technology (PLOT)pharmaceutical development

Get full access to this article

View all access options for this article.

References

Atterwill

C.K.

, Goldfarb

, & Purcell

W.M.

(1999). In Introduction to Approaches to High Throughput Toxicity Screening (ed. Atterwill

C.K.

, Goldfarb

, & Purcell

). London, UK: Taylor & Francis.

Reifferscheid

, & Heil

(1996). Validation of the SOS/umu test using test results of 486 chemicals and comparison with Ames test and carcinogenicity data. Mutation Research 369, 129–145.

Lipinski

C.A.

, Lombardo

, Dominy

B.W.

, & Feeney

P.J.

(1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23, 3–25.

Atterwill

C.K.

, & Purcell

W.M.

(1999). Brain spheroid and other organotypic culture systems in in vitro neurotoxicity. In Neurotoxicity In Vitro (ed. Pentreath

), pp. 213–238. London, UK: Taylor & Francis.

Farr

, & Dunn

R.T.

(1999). Review: Gene Expression Applied to Toxicological Sciences. Toxicological Sciences 50, 1–9.

Kind

, & Hammond

(1999). Early toxic stress or genes: modulation and screening technologies. In Approaches to High Throughput Toxicity Screening (ed. Atterwill

C.K.

, Goldfarb

, & Purcell

). pp. 69–90. London, UK: Taylor & Francis.

EMEA (2000). Report to CPMP on the EMEA seminar on the use of pharmacogenetics in the drug development process (CPMP/1483/00). Web site: http://www.eudra.org/humandocs/Humans/General.htm.

In Vitro Preclinical Lead Optimisation Technologies (PLOTs) in Pharmaceutical Development

Abstract

Keywords

Get full access to this article

References